Article Text

Download PDFPDF
Midostaurin-induced Sweet syndrome in a patient with FLT3-ITD-positive AML
  1. Samer Alkassis1,
  2. Aliza Rizwan1,
  3. Lina Daoud2 and
  4. Jie Chi3
  1. 1Internal Medicine, Detroit Medical Center, Detroit, Michigan, USA
  2. 2Faculty of Medicine, The Hashemite University, Zarqa, Jordan
  3. 3Hematology/Oncology, Karmanos Cancer Institute, Detroit, Michigan, USA
  1. Correspondence to Dr Samer Alkassis; salkassi{at}


Sweet syndrome (SS), also referred as acute febrile neutrophilic dermatosis, is an inflammatory process characterised by the abrupt appearance of erythematous papules or nodules with predominant neutrophilic infiltration in the dermis. Fever and neutrophilia are common presenting features. However, extracellular manifestations, including ocular and musculoskeletal, may occur. SS is divided into three subtypes: classical (or idiopathic), malignancy associated and drug induced. Medication-induced subtype accounts for up to 26% of cases. In recent years, emerging evidence has showed that SS may also occur in neutropenic patients who underwent induction for acute myeloid leukemia (AML). The identification of FMS-like tyrosine kinase 3 (FLT3) gene mutation in approximately 30% of patients with AML has promoted the targeted therapy with FLT3-internal tandem duplication (ITD) inhibitors. Midostaurin, a recently Food and Drug Administration-approved medication for FLT3-ITD-positive AML, was reported once as cause for SS. We report a midostaurin-induced SS with neutropenia in a patient following induction chemotherapy of AML

  • skin
  • dermatology
  • haematology (drugs and medicines)

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors All authors contributed to report preparation, provided critical feedback and helped shape the case. SA took the lead in writing the case report.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.